FOR RESEARCH USE ONLY. The content provided in this article is for educational and informational purposes only and is based on published scientific literature. The compounds discussed are not approved by the FDA for human or veterinary use. They are strictly intended for laboratory research and in vitro experimentation. Pure Health Peptides does not endorse or encourage the use of these products outside of a controlled research setting.
N-Acetyl Semax Amidate is a chemically modified analog of Semax, a synthetic heptapeptide that is itself derived from a fragment of the hormone adrenocorticotropin. Its research interest sits at two levels: the underlying Semax sequence, which is studied for its effects on the neurotrophic factors BDNF and NGF, and the two terminal modifications added to it, N-terminal acetylation and C-terminal amidation, which are classic peptide-chemistry tools for altering enzymatic stability.
This article describes those terminal modifications, the Semax family the compound belongs to, the cognitive-signaling and neurotrophic-pathway research conducted in preclinical models, and how the compound is verified as research material.
Research Snapshot
- N-Acetyl Semax Amidate is a synthetic heptapeptide with the sequence Ac-Met-Glu-His-Phe-Pro-Gly-Pro-NH2, the Semax sequence carrying an acetyl group on its N-terminus and an amide on its C-terminus. Its molecular formula is C39H54N10O10S and its molecular weight is approximately 856 g/mol.
- Semax itself is an analog of the ACTH(4-10) fragment in which the C-terminal residues are replaced by a Pro-Gly-Pro motif, a change that removes the corticotropic activity while retaining the neurotropic activity and extending stability.
- In preclinical research, the Semax sequence has been characterized for increasing the expression of the neurotrophic factors BDNF and NGF in nerve and glial cell systems and in rodent brain regions (Shadrina et al., 2007).
- The N-terminal acetylation and C-terminal amidation are established modifications used in peptide chemistry to reduce susceptibility to exopeptidase degradation, and end-modified analogs like this one are studied for how such changes affect a peptide’s stability.
- Pure Health Peptides supplies N-Acetyl Semax Amidate as a lyophilized Vial. The material is finished and tested in the USA, with every lot routed through independent, ISO/IEC 17025-accredited testing by Ethos Analytics as the exclusive testing partner.
Introduction
N-Acetyl Semax Amidate is best understood as a modified version of a well-studied research peptide. Semax has a substantial preclinical literature centered on the neurotrophic factors, and the interest in the acetylated, amidated form is largely a question of chemistry: what happens to a defined peptide when its two ends are capped in ways known to slow enzymatic breakdown.
That makes the compound a useful tool for two overlapping research conversations, the neurotrophic pathway biology inherited from Semax, and the structure-stability relationships of end-modified peptides.
This article keeps to both frames. It describes the terminal modifications and why they matter, situates the compound within the Semax family and the broader N-Acetyl Amidate group, and covers the cognitive-signaling and neurotrophic research that the Semax sequence is known for, all in the preclinical and in vitro terms the literature uses. It stays within the research-use context and does not extend to any applied use.
The N-Acetyl Amidate Modification
The defining feature of this compound relative to plain Semax is its two terminal modifications. N-terminal acetylation places an acetyl group on the amino terminus of the peptide, and C-terminal amidation converts the carboxyl terminus to an amide. Both are among the most common modifications in peptide chemistry, and both share a purpose: they cap the ends of the peptide, which are the points most exposed to the exopeptidase enzymes that degrade peptides from their termini inward.
Because of this, end-modified analogs are studied for their altered stability profiles. Capping the termini can slow enzymatic degradation and change how a peptide behaves in an experimental system, and comparing a modified analog against its parent sequence is a standard way to probe the contribution of the termini to a peptide’s stability and activity.
N-Acetyl Semax Amidate is exactly such a comparison point: the Semax sequence with both ends modified, offered as a separately characterized research compound alongside the unmodified peptide. This places it within the same design logic as the other N-Acetyl Amidate research peptides, including the N-Acetyl Selank Amidate and N-Acetyl Epithalon Amidate analogs.
Semax Family Structural Context
To understand the sequence at the core of this compound, it helps to start with Semax and its own origin. Semax is a synthetic heptapeptide, Met-Glu-His-Phe-Pro-Gly-Pro, engineered from the ACTH(4-10) fragment of adrenocorticotropin. The engineering was deliberate: the C-terminal portion of the natural ACTH fragment was replaced with a Pro-Gly-Pro motif, a change that removes the hormone’s corticotropic signaling while preserving its neurotropic character and substantially extending the peptide’s stability in plasma.
The result is a compound with the neuro-relevant properties of the ACTH fragment but without the endocrine activity, which is what made Semax a research peptide of interest in the first place.
N-Acetyl Semax Amidate carries that same seven-residue sequence and adds the two terminal caps on top of it. The Phase 1 Semax article covers the unmodified peptide in depth, and this piece extends that coverage to the end-modified analog, completing the N-Acetyl Amidate family alongside the Selank and Epithalon variants. The broader context for these neuropeptides sits in the neuropeptides and cognitive signaling overview.
Cognitive Signaling and Neurotrophic Pathway Research
The research theme most associated with the Semax sequence is its effect on neurotrophic factors. In preclinical work, Semax has been reported to increase the expression of brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF), both at the messenger RNA and protein level, in nerve and glial cell cultures and in rodent brain regions including the hippocampus and basal forebrain.
One study characterized Semax as an analog of ACTH(4-10) that regulates BDNF and trkB receptor expression in the rat hippocampus (Shadrina et al., 2007), and related work examined its action on rapid changes in NGF and BDNF gene expression in the rat brain. The effect on neurotrophic-factor expression is generally treated in the literature as the principal mechanism behind the neuroprotective properties attributed to the peptide in these models.
For N-Acetyl Semax Amidate specifically, the relevant research questions layer the stability chemistry onto that neurotrophic biology: whether and how the terminal modifications change the behavior of the Semax sequence in a given experimental system. Throughout, the appropriate framing is mechanistic and preclinical. These are findings in cell cultures and animal models, and the compound’s role in the catalog is as a defined research peptide for laboratory investigation, not for any applied cognitive use.
Carrier Format and Verification
N-Acetyl Semax Amidate is supplied in a single carrier format, a lyophilized Vial as a white to off-white powder at high HPLC-verified purity. Because it is a defined synthetic sequence prepared by solid-phase peptide synthesis, its identity is straightforward to confirm by mass spectrometry against the theoretical mass, which is the basis of lot-level verification.
Underneath the format is the verification chain. Pure Health Peptides does not manufacture the material; production is sourced from qualified third-party manufacturers, and the material is finished and tested in the USA. Every lot is routed through independent, ISO/IEC 17025-accredited testing by Ethos Analytics as the exclusive testing partner, and each qualified lot’s Certificate of Analysis is published in the COA Library, in the vial section, retrievable by batch ID. For a lyophilized vialed peptide, the appropriate panel extends beyond identity, purity, and quantity to include endotoxin and microbial limits, because contamination can enter downstream of synthesis through handling, lyophilization, vial filling, storage, and transit. The Testing Process page documents how that verification runs, and the same standard applies to every product in the Pure Health Peptides catalog.
Where N-Acetyl Semax Amidate Sits in Neuropeptide Research
For researchers working with the Semax sequence, N-Acetyl Semax Amidate is the end-modified counterpart to a well-characterized peptide: the same neurotrophic-associated sequence, with capped termini that place it in the study of how terminal modifications affect stability.
Its value as a research tool rests on that dual character, the inherited BDNF and NGF pathway biology on one side, and the structure-stability question of the modifications on the other.
As research on the Semax family and on end-modified peptide analogs continues, the compound holds a specific place in the N-Acetyl Amidate group, and it is the direct point of comparison for the September neuropeptide comparison content that follows.
Frequently Asked Questions
What is N-Acetyl Semax Amidate?
It is a synthetic heptapeptide, Ac-Met-Glu-His-Phe-Pro-Gly-Pro-NH2, the Semax sequence carrying an N-terminal acetyl group and a C-terminal amide. Its molecular formula is C39H54N10O10S and its molecular weight is approximately 856 g/mol.
How does it differ from regular Semax?
Regular Semax is the heptapeptide Met-Glu-His-Phe-Pro-Gly-Pro. N-Acetyl Semax Amidate adds two terminal modifications, N-terminal acetylation and C-terminal amidation, which are studied for their effect on the peptide’s susceptibility to enzymatic degradation. The two are supplied as separate, individually characterized research compounds.
What is Semax itself studied for in research?
In preclinical models, the Semax sequence is characterized for increasing expression of the neurotrophic factors BDNF and NGF in nerve and glial cell systems and in rodent brain regions. These are research findings in non-human and in vitro systems.
Why are the acetyl and amide modifications used?
Both cap the ends of the peptide, which are the sites most exposed to the exopeptidase enzymes that degrade peptides from the termini. Capping them is a standard way to study altered stability in end-modified peptide analogs.
What carrier format is N-Acetyl Semax Amidate available in, and how is it verified?
A lyophilized vial. Every lot is finished and tested in the USA and routed through independent, ISO/IEC 17025-accredited testing by Ethos Analytics, with a lot-specific Certificate of Analysis published in the COA Library.
References
- Shadrina M, et al. Semax, an analog of ACTH(4-10) with cognitive effects, regulates BDNF and trkB expression in the rat hippocampus. Brain Research, 2007. https://www.sciencedirect.com/science/article/abs/pii/S0006899306022955
- Neurotrophin gene expression in rat brain under the action of Semax, an analogue of ACTH(4-10). Neuroscience Letters, 2007. https://www.sciencedirect.com/science/article/abs/pii/S0304394007002108
- Dolotov OV, et al. Semax, an analog of adrenocorticotropin (4-10), increases brain-derived neurotrophic factor levels in the rat basal forebrain. Journal of Neurochemistry / peptide neurotrophic research literature.
- International Organization for Standardization / International Electrotechnical Commission. ISO/IEC 17025:2017, General requirements for the competence of testing and calibration laboratories. https://www.iso.org/standard/66912.html
